Ge, J., et al. Development and Preliminary Mechanistic Evaluation of a Novel Liposomal QS-21 and CpG ODNs Adjuvant System for Enhancing Vaccine Immunogenicity. Vaccines (Basel), 2026 Jun 5, 14(6):510. PMID: 42347631

This paper presents a novel liposomal formulation combining QS-21, a potent saponin adjuvant, with CpG ODNs to synergistically enhance Th1-biased immune responses, offering a promising alternative to existing adjuvants like AS01B. 

It demonstrates that liposomal QS-21, when combined with CpG ODNs, not only mitigates QS-21’s hemolytic toxicity but also significantly amplifies cellular immunity through mechanisms involving increased recruitment and activation of dendritic cells, monocytes, and neutrophils, along with upregulation of co-stimulatory molecules and cytokine production. 

This study provides a mechanistic understanding of how saponin-based adjuvants can be optimized through liposomal delivery and rational adjuvant combinations, emphasizing the potential for safer, more effective vaccines targeting intracellular pathogens and tumors. Its relevance lies in advancing saponin adjuvant technology by harnessing synergy with TLR agonists, thereby broadening the scope and efficacy of next-generation vaccine adjuvants.

Click here to access the full scientific paper.